Literature DB >> 10146953

The UK indicative prescribing scheme: background and operation.

J Bligh1, T Walley.   

Abstract

The cost of drugs in the UK has increased at a rate of 4% above inflation over the last ten years. Prescribing in general practice accounts for 80% of the total drugs bill. Within general practice, there is considerable variation in individual prescribing frequency and costs, reflecting demographic, morbidity and professional influences. Recognition that much prescribing is unnecessary and wasteful of resources which may be better used elsewhere in the NHS is a major force behind recent radical changes to the organisation of British general practice. This paper describes the background, implementation and first year of the Indicative Prescribing Scheme (IPS). The IPS is an initiative of the Department of Health in the United Kingdom that aims to introduce greater accountability for, and control over, the costs of prescribing in general practice. Previous attempts to control the costs of drugs to the NHS included efforts to control price, demand, availability; encouraging generic prescribing; and educational initiatives. The IPS was introduced to place downward pressure on expenditure on drugs by improving the quality of prescribing and by eliminating wasteful prescribing. The scheme hinges around the setting of 'indicative prescribing amounts' for each general practice. Practitioners are expected to operate within these guidelines and are provided with regular financial summaries to help them gauge their progress. Additionally, Family Health Service Authorities (the new administrative and managerial body with responsibility for the day-to-day running of primary care services) have engaged medical and pharmaceutical advisers to provide support and information to assist general practitioners with their prescribing. The first year of the scheme has been one of establishment and consolidation. It is too early to judge whether it will be a success. After initial resistance, many doctors are adopting the principles of the scheme and are critically reviewing their prescribing. Greater awareness of the content and influences on prescribing in primary care and of the resource implications for the rest of the NHS of rational prescribing has encouraged dialogue between hospital clinicians, managers and general practitioners.

Mesh:

Year:  1992        PMID: 10146953     DOI: 10.2165/00019053-199202020-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

1.  Protecting the medical commons: who is responsible?

Authors:  H H Hiatt
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

2.  Knowledge of drug costs: a comparison of general practitioners in Scotland and England.

Authors:  M Ryan; B Yule; C Bond; R Taylor
Journal:  Br J Gen Pract       Date:  1992-01       Impact factor: 5.386

3.  FHSA medical advisers: friends or foes?

Authors:  T Walley; J Bligh
Journal:  BMJ       Date:  1992-01-18

4.  Uncomfortable prescribing decisions: a critical incident study.

Authors:  C P Bradley
Journal:  BMJ       Date:  1992-02-01

5.  Funding family health services.

Authors:  D Taylor
Journal:  BMJ       Date:  1991-09-07

6.  A survey of 17,301 prescriptions on from E.C. 10.

Authors:  D M DUNLOP; T L HENDERSON; R S INCH
Journal:  Br Med J       Date:  1952-02-09

7.  Prescribing in general practice. A review by the RCGP Prescribing Fellow in Scotland.

Authors:  J D Gilleghan
Journal:  Occas Pap R Coll Gen Pract       Date:  1991-11

8.  Indicative drug budgets for general practitioners: a prescription for change.

Authors:  B O'Brien
Journal:  BMJ       Date:  1989-04-08

9.  Prescribing--a suitable case for treatment.

Authors:  C M Harris; B Jarman; E Woodman; P White; J S Fry
Journal:  J R Coll Gen Pract Occas Pap       Date:  1984-01

10.  The general practice formulary--its role in rational therapeutics.

Authors:  P E Green
Journal:  J R Coll Gen Pract       Date:  1985-12
View more
  13 in total

Review 1.  Drug rationing in the UK National Health Service. Current status and future prospects.

Authors:  T Walley; A Haycox; S Barton
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

2.  Overview of international pharmacy pricing.

Authors:  A I Wertheimer; S K Grumer
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

3.  General practice fundholding in the United Kingdom: is it working?

Authors:  H Glennerster
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

4.  Is there a need for an independent centre for pharmacoeconomics in the UK?

Authors:  T Walley; R T Edwards
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

Review 5.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

6.  Health economics in primary care in the UK: containment of drug costs.

Authors:  T Walley; R T Edwards
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 7.  An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.

Authors:  J P Griffin
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 8.  Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding.

Authors:  T Walley; R Wilson; J Bligh
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

9.  A UK national prescribing list?

Authors:  T Walley
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

10.  Influences on prescribing in non-fundholding general practices.

Authors:  M P Eccles; J Soutter; D N Bateman; M Campbell; J M Smith
Journal:  Br J Gen Pract       Date:  1996-05       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.